Treanda maker gets SEC subpoena

According to the pharmaceutical blog Pharmalot, Cephalon, the company that makes Treanda (bendamustine) has become the subject of a Securities and Exchange Commission investigation into possible marketing of the drug in unapproved indications.

Cephalon is already functioning under a Corporate Integrity Agreement after the Justice Department busted them in 2008 for marketing several medications for unapproved indications. Cephalon also paid a few hundred million dollars in fines.

Treanda is currently approved in the treatment of:

- Patients with indolent B-cell non-Hodgkin lymphoma (NHL) that progressed during or within six months of treatment with Rituxan or a Rituxan-containing regimen.
- Patients with chronic lymphocytic leukemia (CLL).

While doctors are free to use drugs off-label, a pharmaceutical company can only market a drug under its approved indications.

Further Reading

NCI: Treanda
Pharmalot entry on Cephalon
From the SEC

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap